Rani Therapeutics Holdings RANI 深 滬
等待開盤 09-11 09:30:00 美东时间
0.4916
-0.008
-1.56%
華盛通- 最 高0.5091
- 今 開0.5062
- 成交量 9.22万股
- 最 低 0.4908
- 昨 收 0.4994
- 總市值 1650.32万
- 52周最高 3.75
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 0.387
- 委 比 33.33%
- 總股本 3357.03万
- 歷史最高 36.27
- 量 比 0.50
- 振 幅 3.66%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rani Therapeutics Hldgs Q2 EPS $(0.18) Beats $(0.24) Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 24.05 percent. This is a 30.77 percent increase over losses of $(0.26) per
08-08 04:53
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics reported Q2 2025 financial results, highlighting a strategic research collaboration with Chugai for two undisclosed molecules, preclinical data on its oral bispecific GLP-1/GLP-2 receptor agonist RT-114 demonstrating bioequivalence to subcutaneous delivery, and plans to initiate a Phase 1 trial for obesity treatment. The company also announced a $4.3 million warrant inducement transaction and a $3.0 million registered direct off...
08-07 20:05
Rani Therapeutics Announces New Securities Purchase Agreement
Rani Therapeutics Holdings ( ($RANI) ) has issued an announcement. On July 14, ...
07-17 02:27
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Rani Therapeutics has entered into a securities purchase agreement with a single institutional investor to sell 4,354,000 shares of its Class A common stock at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999. Maxim Group LLC is acting as the sole placement agent. The offering is expected to close on July 16, 2025, with gross proceeds of approximately $3.0 million. The securities are being offered under a "shelf" registrati...
07-15 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Rani Therapeutics Unveils Data on Robotic Pill That Matches Injections in Canine Study at ENDO 2025
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present
07-14 17:02
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rani Therapeutics will present preclinical data on its RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco. The presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines," will be a poster presentation on July 14 from 12:00 PM to 1:30 PM PT. Rani Therapeutics, a clinical-stage biotherapeutic...
07-14 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
